01 1Curia
01 1DEUCRAVACITINIB
01 1U.S.A
01 1Active
01 1Complete
GDUFA
DMF Review : Complete
Rev. Date : 2025-04-23
Pay. Date : 2025-04-04
DMF Number : 41626
Submission : 2025-03-28
Status : Active
Type : II
20
Curia Spain Sau, based in U.S.A, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
They are recognized for Curia- A partner for the pharma and biotech industries to improve patient outcomes & quality of life.
One of their notable products is DEUCRAVACITINIB, with a corresponding US DMF Number 41626.
Remarkably, this DMF maintains an Active status since its submission on March 28, 2025, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of April 23, 2025, and payment made on April 04, 2025, indicating their dedication to facilitating drug approvals, Categorized as Type II
